Anzeige
Mehr »
Donnerstag, 03.07.2025 - Börsentäglich über 12.000 News
+210 % Kursgewinn Year to Date: Neuausrichtung nimmt Fahrt auf - jetzt exklusives CEO-Interview ansehen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
498 Leser
Artikel bewerten:
(0)

New Clinical Trial Indicates Allen Carr's Easyway to Stop Smoking is at Least Twice as Effective as the Health Service

LONDON, October 26, 2018 /PRNewswire/ --

Allen Carr is now a proven, effective drug-free alternative to nicotine patches, gum, and e-cigarettes taking the treatment of smokers out of the hands of Big Tobacco and Big Pharma

The leading stop smoking treatment, Allen Carr's Easyway to Stop Smoking Seminars, which is completely drug free, has today received a major boost as a fully independent Randomised Control Trial (RCT) on behalf of the Irish Government, has found that it is twice as effective as the techniques currently offered by the Irish Health Service (which include nicotine patches, e-cigarettes and gum). The trial results have been reported in the BMJ's Tobacco Control Journal on 26 October 2018, which can be found here:

John Dicey, Global CEO of Allen Carr's Easyway comments:

"This is landmark day as, for the first time, it presents the results of the programme's performance in a robust clinical trial. There is no doubt that being a cognitive (spoken) method doesn't make it particularly suitable for this kind of clinical trial but even in these circumstances we're delighted that the method was found to be twice effective as the current treatments available in Ireland. We are also expecting the findings of a London-based RCT to be published soon, which should confirm that Allen Carr's Easyway method is better than, or at least as good as, the current gold standard One-to-One NHS Stop Smoking Service. This should pave the way for this drug-free, quick & easy method to be made available via the Irish Health Service and the NHS."

The results of the trial show that Allen Carr's Easyway quit rates wereALWAYS superior to Quit.ie, consistently achieving higher quit rates at 1, 3, 6 and 12 months.

Brenda Sweeney, Allen Carr's Easyway Ireland's Managing Director said:

"These results should give the Irish Health Service Executive (HSE) the confidence to make Allen Carr's Easyway to Stop Smoking Seminar programme available as an exciting alternative to nicotine patches, nicotine gum, and other treatments in Ireland. Working together, we can now provide realistic and more cost-effective opportunity to free Ireland of smoking - after all, that was the reason that the Irish Government commissioned the study."

Professor Sofia Ravara, Chair of Group for the influential European Respiratory Society Tobacco Control Committee welcomes the study with enthusiasm saying:
"I found the study very useful and hope we don't have to wait another 30 years for Allen Carr to be a validated smoking cessation method."

It is believed that this is the first time that such a therapy has been subjected to the rigours of a full RCT. The Allen Carr's Easyway to Stop Smoking Seminar Programme does not rely on any nicotine, nicotine substances, patches or other pharmaceuticals. It challenges the reasons why people smoke, and most people report that they not only stop smoking, but actually lose the desire to smoke.

John Dicey continues:

"Adding our programme to their menu of services would not only save hundreds and thousands more lives but also save the HSE and the NHS millions of pounds a year. While many health bodies continue to promote the use of NRT, Champix, Zyban and e-cigarettes, it's surely essential that they also provide an alternative which is 100% safe, drug-free and proven - especially one that would excite and encourage smokers to seek assistance to quit. Allen Carr's Easyway organisation is even prepared to offer its famous money back guarantee to the HSE and the NHS. With nicotine patches and gum alone currently costing the NHS in excess of £27million per year and smoking estimated to cost the health service in excess of £2.7 billion a year, we are confident that introducing our method will make a major impact to success rates and cost savings for the health service."

For further information visit www.allencarr.com

Notes to Editors:

  • Allen Carr's Easyway is the world's most successful stop smoking method. Over 30 years, Allen Carr's Easyway method has cured an estimated 30 million people of their addiction worldwide.
  • Interviews with John Dicey, Worldwide Managing Director & CEO are available on request.
  • John was an 80 a day smoker before he successfully quit using Allen Carr's method.
  • Complimentary sessions for media contacts or test cases available on request.
  • Allen Carr's Easyway has clinics in 50+ countries across the globe and the method is endorsed by a wide variety of celebrities and opinion formers.
  • Case studies available on request.
  • Allen Carr's Easyway to Stop Smoking sessions are available throughout the UK and Ireland, at a cost of £279/€320.00 per person, including a money back guarantee.
© 2018 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.